163 related articles for article (PubMed ID: 10689709)
1. "To the heart of the matter...".
Kamen BA; Drachtman R
Pediatr Hematol Oncol; 2000; 17(1):5-7. PubMed ID: 10689709
[No Abstract] [Full Text] [Related]
2. Adjuvant anthracyclines and taxanes: quantifying the costs of therapeutic advances in breast cancer.
Morris PG; Bach PB
Onkologie; 2009 Sep; 32(8-9):464-6. PubMed ID: 19745589
[No Abstract] [Full Text] [Related]
3. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.
Wouters KA; Kremer LC; Miller TL; Herman EH; Lipshultz SE
Br J Haematol; 2005 Dec; 131(5):561-78. PubMed ID: 16351632
[TBL] [Abstract][Full Text] [Related]
4. Outpatient cancer drug costs: changes, drivers, and the future.
Halbert RJ; Zaher C; Wade S; Malin J; Lawless GD; Dubois RW
Cancer; 2002 Feb; 94(4):1142-50. PubMed ID: 11920485
[TBL] [Abstract][Full Text] [Related]
5. [Economic effects of "molecular" medicine].
Riemann JF
Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1740. PubMed ID: 17713881
[No Abstract] [Full Text] [Related]
6. [Control of the myocardial pump function during cytostatic treatment with anthracycline].
Hesse B; Mouridsen HT; Schaadt BK; Meyer C
Ugeskr Laeger; 1996 Aug; 158(33):4628-30. PubMed ID: 8760518
[No Abstract] [Full Text] [Related]
7. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.
Mavinkurve-Groothuis AM; Groot-Loonen J; Bellersen L; Pourier MS; Feuth T; Bökkerink JP; Hoogerbrugge PM; Kapusta L
Pediatr Blood Cancer; 2009 May; 52(5):631-6. PubMed ID: 19127569
[TBL] [Abstract][Full Text] [Related]
8. Commentary: anthracyclines in early-stage breast cancer: is it the end of an era?
Pritchard KI
Oncologist; 2009 Oct; 14(10):959-62. PubMed ID: 19819915
[No Abstract] [Full Text] [Related]
9. Anthracyclines.
Hamilton D; Batist G
Cancer Chemother Biol Response Modif; 2005; 22():19-33. PubMed ID: 16110606
[No Abstract] [Full Text] [Related]
10. [Methodology of pharmacoeconomic studies in oncology].
Ballatori E
Recenti Prog Med; 2008 Jan; 99(1):42-7. PubMed ID: 18389873
[TBL] [Abstract][Full Text] [Related]
11. Ya gotta have heart.
Lange BJ; Woods WG
Pediatr Blood Cancer; 2011 Apr; 56(4):513-4. PubMed ID: 21298732
[No Abstract] [Full Text] [Related]
12. Wise up: do not do it without protection!
Sallan SE; Lipshultz SE
Pediatr Blood Cancer; 2005 Dec; 45(7):872-3. PubMed ID: 16206201
[No Abstract] [Full Text] [Related]
13. Researching the cost of research.
Wright JR; Levine MN
J Clin Oncol; 2003 Nov; 21(22):4081-2. PubMed ID: 14559890
[No Abstract] [Full Text] [Related]
14. Anthracycline cardiotoxicity in childhood.
Ruggiero A; Ridola V; Puma N; Molinari F; Coccia P; De Rosa G; Riccardi R
Pediatr Hematol Oncol; 2008 Jun; 25(4):261-81. PubMed ID: 18484471
[TBL] [Abstract][Full Text] [Related]
15. Anthracycline cardiotoxicity.
Horan PG; McMullin MF; McKeown PP
Eur Heart J; 2006 May; 27(10):1137-8. PubMed ID: 16611672
[No Abstract] [Full Text] [Related]
16. Anthracycline-induced heart failure.
van Dalen EC
Nat Clin Pract Oncol; 2007 Dec; 4(12):E1. PubMed ID: 18037871
[No Abstract] [Full Text] [Related]
17. Is there more for us to learn from oncology?: Examining the implications of anthracycline effects on the young heart.
Sawyer DB
Circulation; 2010 Feb; 121(5):623-5. PubMed ID: 20100976
[No Abstract] [Full Text] [Related]
18. Should anthracyclines and dexrazoxane be used for children with cancer?
van Dalen EC; van den Berg H; Raphaël MF; Caron HN; Kremer LC
Lancet Oncol; 2011 Jan; 12(1):12-3. PubMed ID: 21195321
[No Abstract] [Full Text] [Related]
19. Anticancer agents and cardiotoxicity.
Ng R; Better N; Green MD
Semin Oncol; 2006 Feb; 33(1):2-14. PubMed ID: 16473642
[TBL] [Abstract][Full Text] [Related]
20. [Chemotherapeutics-induced heart failure].
Paulides M; Wojnowski L
Med Klin (Munich); 2007 Jul; 102(7):574-8. PubMed ID: 17634876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
